Article Versions Notes

Martin NT, Crupi MJF, Taha Z, Poutou J, Whelan JT, Vallati S, Petryk J, Marius R, Austin B, Azad T, et al. Engineering Rapalog-Inducible Genetic Switches Based on Split-T7 Polymerase to Regulate Oncolytic Virus-Driven Production of Tumour-Localized IL-12 for Anti-Cancer Immunotherapy. Pharmaceuticals. 2023; 16(5):709. https://doi.org/10.3390/ph16050709

Martin, Nikolas T., Mathieu J. F. Crupi, Zaid Taha, Joanna Poutou, Jack T. Whelan, Sydney Vallati, Julia Petryk, Ricardo Marius, Bradley Austin, Taha Azad, and et al. 2023. "Engineering Rapalog-Inducible Genetic Switches Based on Split-T7 Polymerase to Regulate Oncolytic Virus-Driven Production of Tumour-Localized IL-12 for Anti-Cancer Immunotherapy" Pharmaceuticals 16, no. 5: 709. https://doi.org/10.3390/ph16050709

Martin, N. T., Crupi, M. J. F., Taha, Z., Poutou, J., Whelan, J. T., Vallati, S., Petryk, J., Marius, R., Austin, B., Azad, T., Boulanger, M., Burgess, T., Sanders, I., Victoor, C., Dickinson, B. C., Diallo, J. -S., Ilkow, C. S., & Bell, J. C. (2023). Engineering Rapalog-Inducible Genetic Switches Based on Split-T7 Polymerase to Regulate Oncolytic Virus-Driven Production of Tumour-Localized IL-12 for Anti-Cancer Immunotherapy. Pharmaceuticals, 16(5), 709. https://doi.org/10.3390/ph16050709